Effects of probiotic supplementation in patients with type 2 diabetes: Systematic review and meta-analysis

Nutrition Reviews

Volumn 74, Issue 12, 2016, Pages 774-784

  Akbari, Vajihe ^a   Hendijani, Fatemeh ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PROBIOTIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADVERSE OUTCOME; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; CONCENTRATION PROCESS; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG EFFECT; EARLY INTERVENTION; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCOPUS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WEB OF SCIENCE; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; PROBIOTICS;

EID: 85015612156     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nuw039     Document Type: Article

References (53)

1. World Health Organization. Global status report on noncommunicable diseases 2014 Fact sheet no. 312. http://www.whoiran.org/pdf-files/WHO%20Fact%20Sheet%20312%20-%20Diabetes.pdf. Updated January 2015. Accessed October 2015.
2. Cree-Green M, Triolo TM, Nadeau KJ. Etiology of insulin resistance in youth with type 2 diabetes. Curr Diab Rep. 2013;13:81-88.
3. Mizokami-Stout K, Cree-Green M, Nadeau KJ. Insulin resistance in type 2 diabetic youth. Curr Opin Endocrinol Diabetes Obes. 2012;19:255-262.
4. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55-60.
5. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5:e9085. doi: 10.1371/journal.pone.0009085.
6. Sato J, Kanazawa A, Ikeda F, et al. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care. 2014;37:2343-2350.
7. Soyucen E, Gulcan A, Aktuglu-Zeybek AC, et al. Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int. 2014;56:336-343.
8. Bekkering P, Jafri I, van Overveld FJ, et al. The intricate association between gut microbiota and development of type 1, type 2 and type 3 diabetes. Expert Rev Clin Immunol. 2013;9:1031-1041.
9. Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 2013;27:73-83.
10. Everard A, Lazarevic V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 2011;60:2775-2786.
11. Lin CH, Lin CC, Shibu MA, et al. Oral Lactobacillus reuteri GMN-32 treatment reduces blood glucose concentrations and promotes cardiac function in rats with streptozotocin-induced diabetes mellitus. Br J Nutr. 2014;111:598-605.
12. Yadav H, Jain S, Sinha PR. Effect of skim milk and dahi (yogurt) on blood glucose, insulin, and lipid profile in rats fed with high fructose diet. J Med Food. 2006;9:328-335.
13. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr. 2010;104:1831-1838.
14. Asemi Z, Samimi M, Tabassi Z, et al. Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial. Eur J Clin Nutr. 2013;67:71-74.
15. Shakeri H, Hadaegh H, Abedi F, et al. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids. 2014;49:695-701.
16. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, West Sussex, England: The Cochrane Collaboration and John Wiley & Sons Ltd; 2008.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
18. Higgins J, Altman D, Sterne J. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Chichester, West Sussex, England: The Cochrane Collaboration and John Wiley & Sons Ltd; 2011:8.1-8.53.
19. Harris R, Bradburn M, Deeks J, et al. metan: fixed-and random-effects meta-analysis. Stata J. 2008;8:3-28.
20. Lipsey MW, Wilson DB. Practical Meta-Analysis. Thousand Oaks, CA: SAGE Publications; 2001.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
22. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ. 2007;176:1091-1096.
23. Hosseinzadeh P, Javanbakht MH, Mostafavi SA, et al. Brewer's yeast improves glycemic indices in type 2 diabetes mellitus. Int J Prev Med. 2013;4:1131-1138.
24. Bahijiri SM, Mira SA, Mufti AM, et al. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. Saudi Med J. 2000;21:831-837.
25. Rabinowitz MB, Gonick HC, Levin SR, et al. Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diabetes Care. 1983;6:319-327.
26. Hove KD, Brøns C, Færch K, et al. Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study. Eur J Endocrinol. 2015;172:11-20.
27. Mobini R, Kovatcheva P, Tremaroli V, et al. Metabolic effects of dietary supplementation with Lactobacillus reuteri DSM 17938: a randomised proof-of-concept study in type 2 diabetes. Paper presented at: 51st EASD (European Association for the Study of Diabetes) Annual Meeting; September 14-18, 2015; Stockholm, Sweden. Abstract 826.
28. Martino H, Tonucci L, Santos K, et al. Effects of probiotics on glycemic control and inflammation in type 2 diabetes mellitus: a randomized, double-blind, placebocontrolled Study. FASEB J. 2015;29(suppl):922.6. doi:10.1096/fj.1530-6860.
29. Ejtahed HS, Mohtadi Nia J, Homayouni Rad A, et al. The effects of probiotic and conventional yoghurt on diabetes markers and insulin resistance in type 2 diabetic patients: a randomized controlled clinical trial. Iran J Endocrinol Metabol. 2011;13:1-8.
30. Ostadrahimi A, Taghizadeh A, Mobasseri M, et al. Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health. 2015;44:228-237.
31. Mazloom Z, Yousefinejad A, Dabaghmanaesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci. 2013;38:38-43.
32. Mohamadshahi M, Veissi M, Haidari F, et al. Effects of probiotic yogurt consumption on lipid profile in type 2 diabetic patients: a randomized controlled clinical trial. J Res Med Sci. 2014;19:531-536.
33. Bayat A, Heydaribeni M, Feizi A, et al. The effect of pumpkin and probiotic yogurt consumption separately or/and simultaneously on type II diabetes. J Isfahan Med School. 2014;32:580-589.
34. Judiono J, Hadisaputro S, Indranila KS, et al. Effects of clear kefir on biomolecular aspects of glycemic status of type 2 diabetes mellitus (T2DM) patients in Bandung, West Java [study on human blood glucose, c peptide and insulin]. Funct Foods Health Dis 2014;4:340-348.
35. Tajadadi-Ebrahimi M, Bahmani F, Shakeri H, et al. Effects of daily consumption of synbiotic bread on insulin metabolism and serum high-sensitivity C-reactive protein among diabetic patients: a double-blind, randomized, controlled clinical trial. Ann Nutr Metab. 2014;65:34-41.
36. Matthews D, Hosker J, Rudenski A, et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
37. Ruan Y, Sun J, He J, et al. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. PloS One. 2015;10:e0132121. doi:10.1371/journal.pone.0132121.
38. Kasińska M, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a metaanalysis. Pol Arch Med Wewn. 2015;125:803-813.
39. Cani PD, Osto M, Geurts L, et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3:279-288.
40. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772.
41. Griffiths EA, Duffy LC, Schanbacher FL, et al. In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice. Dig Dis Sci. 2004;49:579-589.
42. Siebler J, Galle PR, Weber MM. The gut-liver-axis: endotoxemia, inflammation, insulin resistance and NASH. J Hepatol. 2008;48:1032-1034.
43. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-546.
44. Chapman C, Gibson GR, Rowland I. Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr. 2011;50:1-17.
45. Fujimori S, Tatsuguchi A, Gudis K, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22:1199-1204.
46. Suharja AA, Henriksson A, Liu SQ. Impact of Saccharomyces cerevisiae on viability of probiotic Lactobacillus rhamnosus in fermented milk under ambient conditions. J Food Process Preserv. 2014;38:326-337.
47. Tilg H, Adolph TE. Influence of the human intestinal microbiome on obesity and metabolic dysfunction. Curr Opin Pediatr. 2015;27:496-501.
48. Lee SJ, Bose S, Seo J-G, et al. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: a randomized double-blind controlled clinical trial. Clin Nutr. 2014;33:973-981.
49. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027-1131.
50. van Olden C, Groen AK, Nieuwdorp M. Role of intestinal microbiome in lipid and glucose metabolism in diabetes mellitus. Clin Ther. 2015;37:1172-1177.
51. Lin HV, Frassetto A, Kowalik EJ Jr, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012;7:e35240. doi:10.1371/journal.pone.0035240.
52. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718-15723.
53. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115:178-181.